Presentation and publication of clinical and biomarker data, regulatory developments, and 100mg BID dosing regimen support advancement of the neflamapimod clinical development program in dementia with Lewy bodies
Placebo-controlled results of RewinD-LB clinical trial published in Alzheimer’s Research & Therapy provides further evidence of the potential of neflamapimod to slow clinical disease progression in DLB
On average, reduction in plasma neurofilament light levels was observed during the first 12 weeks of treatment, with a greater decline in participants with baseline levels at or above the median 24-week biomarker data
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience FDA removal of the prior drug exposure limit provides greater dosing flexibility in future
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that
12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting nfvPPA, the type of frontotemporal dementia (FTD) most commonly associated with tau pathology,
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders ("CervoMed" or the "Company"), today
Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United Kingdom’s Innovative
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that
Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines Neflamapimod selected for the ILAP by joint
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) New analyses of Phase
Interim biomarker data accepted for presentation at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference Recent peer-reviewed data published in Nature Neuroscience demonstrate relevance of p38α as a
Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain atrophy, as well as
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced the
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has
